References
Martin-Loeches I, Antonelli M, Cuenca-Estrella M et al (2019) ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med 45:789–805
Dreyfuss D, Ricard J-D, Gaudry S (2013) Amphotericin B deoxycholate for candidiasis in intensive care unit patients revisited: medical, ethical, and financial implications. Am J Respir Crit Care Med 187:661–663
Limper AH, Knox KS, Sarosi GA et al (2011) An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 183:96–128
Funding
None
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
DR expert for Astellas (past), SG and DD: none.
Human and animal rights
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Roux, D., Gaudry, S. & Dreyfuss, D. Conventional amphotericin B should remain in the armamentarium as a cheap and efficient waiting solution. Intensive Care Med 46, 558–559 (2020). https://doi.org/10.1007/s00134-019-05782-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-019-05782-z